Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.
The FDA needs more time to review Exelixis's new cancer medicine, pushing a decision to March 2027. When companies face delays on important medicines, watch how confident the company stays about their business and what they say earnings will be.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.